Abstract 409P
Background
Chemotherapy is the basic treatments for lung cancer, and nausea and vomiting is one of the most common adverse event of chemotherapy, which decrease the life quality. As a result, how to prevent chemotherapy induced nausea and vomiting(CINV) is an important subject faced by oncologists. The granisetron transdermal delivery system (GTDS) has been developed to deliver granisetron continuously over 7 days to prevent CINV. Some previous cases receiving multiday highly emetogenic chemotherapy (HEC) regimens showed that the GTDS plus dexamethasone was not inferior to the GTDS plus dexamethasone and aprepitant. But there is no similar studies at home and abroad.
Methods
Our study prospectively assessed the non-inferiority of the GTDS plus dexamethasone to the GTDS plus dexamethasone and aprepitant in patients receiving multiday HEC. The primary endpoint was the proportion of patients with complete control of CINV from chemotherapy initiation until 24 h after final administration. The study has already enrolled 40 patients, 21 patients with two regimens, and 19 patients with three regimens before receiving multiday HEC.
Results
Between January 2019 and June 2020, 40 patients was recruited in the analysis. The GTDS plus dexamethasone group displayed non-inferiority to The GTDS plus dexamethasone and aprepitant group, complete control was achieved by 63.6% of patients in the two regimens group, and 65.4% in the three regimens group (P>0.05). Both treatments were well tolerated, the most common adverse events are manageable.
Conclusions
Current guidelines for the management of multiday HEC recommend three regimens therapy. Our study indicate that the two regimens therapy provides effective, well-tolerated control of multiday HEC. It offers a alternative route for delivering two regimens for up to 7 days that is as effective as three regimens.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session